In This Issue

• From the IASLC Tobacco Control Committee

Editorials

• Reprint of “Introduction to 2021 WHO Classification of Thoracic Tumors”
• Rethinking the Status of Chemotherapy Combined With the Addition of Cytotoxic T-Lymphocyte–Associated Antigen 4 Inhibition and Programmed Death 1 or Programmed Death-Ligand 1 Blockade
• Informing Patient Surveillance for the Growing Number of Survivors of Lung Cancer
• The Magic of ADAURA?
• STK11 and KEAP1 Mutations in Lung Adenocarcinoma: Solving the Puzzle Continues

Editorial - Lung Cancer Worldwide

• Lung Cancer in Japan

State of the Art: Concise Review

• The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015

Original Articles

• Incidence of Smoking-Related Second Primary Cancers After Lung Cancer in Germany: An Analysis of Nationwide Cancer Registry Data
• Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
• Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790MD NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
• Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
• CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC
• Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors

Brief Reports

• Molecular Characterization of Peritoneal Mesotheliomas
• Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations

Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest. Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic science studies must have direct clinical and translational relevance.

Authors are also welcome to submit to the journal's open access companion title, JTO Clinical and Research Reports, which welcomes a range of manuscripts from subset analyses of published trials to high-quality case reports